List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6134827/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study. Arthritis Care and Research, 2023, 75, 410-422.	1.5	2
2	Underdetection of Interstitial Lung Disease in Juvenile Systemic Sclerosis. Arthritis Care and Research, 2022, 74, 364-370.	1.5	13
3	Discrete Choice Experiment on a Magnetic Resonance Imaging Scoring System for Temporomandibular Joints in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 308-316.	1.5	9
4	Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort. Arthritis Care and Research, 2022, 74, 1575-1584.	1.5	13
5	Variations in Pediatric Rheumatology Workforce and Care Processes Across Canada. Journal of Rheumatology, 2022, 49, 197-204.	1.0	2
6	Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. Human Molecular Genetics, 2022, 31, 2471-2481.	1.4	9
7	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and ACS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.5	31
8	Consensus Approach to a Treat-to-target Strategy in Juvenile Idiopathic Arthritis Care: Report From the 2020 PR-COIN Consensus Conference. Journal of Rheumatology, 2022, 49, 497-503.	1.0	4
9	OUP accepted manuscript. Rheumatology, 2022, , .	0.9	0
10	The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12690.	1.0	37
11	The importance of rigorous methods in observational comparative effectiveness studies of rare diseases: comment on the article by Ruperto et al. Arthritis and Rheumatology, 2022, 74, 912-913.	2.9	0
12	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp> / <scp>PRAAS</scp> , <scp>SAVI</scp> , and <scp>AGS</scp> . Arthritis and Rheumatology, 2022, 74, 735-751.	2.9	23
13	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis and Rheumatology, 2022, 74, 570-585.	2.9	11
14	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2022, 74, 553-569.	2.9	68
15	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. Arthritis Care and Research, 2022, 74, 505-520.	1.5	15
16	A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort. Arthritis and Rheumatology, 2022, 74, 1409-1419.	2.9	7
17	Feasibility of the wingate anaerobic exercise test as a clinical measure in patients with juvenile dermatomyositis. Pediatric Rheumatology, 2022, 20, 21.	0.9	0
18	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2022, 74, 521-537.	1.5	27

#	Article	lF	CITATIONS
19	Management of Calcinosis Cutis in Rheumatic Diseases. Journal of Rheumatology, 2022, 49, 980-989.	1.0	13
20	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Annals of the Rheumatic Diseases, 2022, 81, 1203-1205.	0.5	4
21	Predicting Macrophage Activation Syndrome in Childhood-onset Systemic Lupus Erythematosus Patients at Diagnosis. Journal of Rheumatology, 2021, 48, 1450-1457.	1.0	10
22	Correlation of a Modified Disease Activity Score (DAS) with the Validated Original DAS in Patients with Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 101-104.	1.0	3
23	Pilot Study of the Juvenile Dermatomyositis Consensus Treatment Plans: A CARRA Registry Study. Journal of Rheumatology, 2021, 48, 114-122.	1.0	9
24	The <i>iCanCope</i> pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial. Rheumatology, 2021, 60, 196-206.	0.9	26
25	The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study. Journal of Rheumatology, 2021, 48, 434-441.	1.0	9
26	Understanding Early Hemophilic Arthropathy in Children and Adolescents Through MRI T 2 Mapping. Journal of Magnetic Resonance Imaging, 2021, 53, 827-837.	1.9	5
27	Choosing the frequency of follow-up in longitudinal studies: Is more necessarily better?. Research Methods in Medicine & Health Sciences, 2021, 2, 61-67.	0.7	2
28	Measuring clinical utility in the context of genetic testing: a scoping review. European Journal of Human Genetics, 2021, 29, 378-386.	1.4	12
29	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2021, 80, 406-408.	0.5	53
30	Causal pathways to health-related quality of life in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Rheumatology, 2021, 60, 4691-4702.	0.9	9
31	Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patients' experiences. Pediatric Rheumatology, 2021, 19, 17.	0.9	1
32	Functional limitations caused by simple bone cysts. Journal of Children's Orthopaedics, 2021, 15, 178-182.	0.4	0
33	Patterns of joint damage in severe haemophilia A treated with prophylaxis. Haemophilia, 2021, 27, 666-673.	1.0	1
34	Electronic forms for patient reported outcome measures (PROMs) are an effective, time-efficient, and cost-minimizing alternative to paper forms. Pediatric Rheumatology, 2021, 19, 67.	0.9	12
35	Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12531.	1.0	18
36	Assessing the Reliability of the OMERACT Juvenile Idiopathic Arthritis Magnetic Resonance Scoring System for Temporomandibular Joints (JAMRIS-TMJ). Journal of Clinical Medicine, 2021, 10, 4047.	1.0	12

#	Article	IF	CITATIONS
37	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology, 2021, 73, 1898-1909.	2.9	19
38	Characterization of physical literacy in children with chronic medical conditions compared with healthy controls: a cross-sectional study. Applied Physiology, Nutrition and Metabolism, 2021, 46, 1073-1082.	0.9	7
39	Comparing the Measurement Properties and Preferability of Patient-reported Outcome Measures in Pediatric Rheumatology: PROMIS vs CHAQ. Journal of Rheumatology, 2021, 48, 1065-1072.	1.0	9
40	Magnetic resonance imaging in boys with severe hemophilia A: Serial and endâ€ofâ€study findings from the Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12565.	1.0	4
41	Social participation and hemophilia: Selfâ€perception, social support, and their influence on boys in Canada. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12627.	1.0	3
42	Worse Quality of Life, Function, and Pain in Children With Enthesitis, Irrespective of Their Juvenile Arthritis Category. Arthritis Care and Research, 2020, 72, 441-446.	1.5	15
43	Realâ€World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort. Arthritis Care and Research, 2020, 72, 897-906.	1.5	14
44	Towards therapeutic drug monitoring of TNF inhibitors for children with juvenile idiopathic arthritis: a scoping review. Rheumatology, 2020, 59, 386-397.	0.9	19
45	Using Registry Data to Understand Disease Evolution in Inflammatory Myositis and Other Rheumatic Diseases. Current Rheumatology Reports, 2020, 22, 2.	2.1	2
46	Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia, 2020, 26, 1072-1080.	1.0	14
47	WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia, 2020, 26, 1-158.	1.0	915
48	Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 652-658.	1.0	10
49	Hemophilia prophylaxis adherence and bleeding using a tailored, frequencyâ€escalated approach: The Canadian Hemophilia Primary Prophylaxis Study. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 318-325.	1.0	16
50	Estimation of causal effects with repeatedly measured outcomes in a Bayesian framework. Statistical Methods in Medical Research, 2020, 29, 2507-2519.	0.7	1
51	Teens Taking Charge: A Randomized Controlled Trial of a Web-Based Self-Management Program With Telephone Support for Adolescents With Juvenile Idiopathic Arthritis. Journal of Medical Internet Research, 2020, 22, e16234.	2.1	13
52	Developing comparative effectiveness studies for a rare, understudied pediatric disease: lessons learned from the CARRA juvenile localized scleroderma consensus treatment plan pilot study. Pediatric Rheumatology, 2019, 17, 43.	0.9	10
53	Developing a new scoring scheme for the Hemophilia Joint Health Score 2.1. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 405-411.	1.0	13
54	Postâ€ŧhrombotic syndrome in children: Measurement properties of CAPTSure, a new diagnostic tool. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 652-657.	1.0	11

#	Article	IF	CITATIONS
55	American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2019, 71, 579-590.	1.5	15
56	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. Arthritis Care and Research, 2019, 71, 703-716.	1.5	176
57	Impact of prophylaxis on healthâ€related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 397-404.	1.0	12
58	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‧ystemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care and Research, 2019, 71, 717-734.	1.5	225
59	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Nonâ€6ystemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis and Rheumatology, 2019, 71, 846-863.	2.9	110
60	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. Arthritis and Rheumatology, 2019, 71, 864-877.	2.9	57
61	European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis—the SHARE initiative. Rheumatology, 2019, 58, 1607-1616.	0.9	165
62	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology, 2019, 46, 1006-1013.	1.0	34
63	Patient and caregiver engagement in research: factors that influence co-enrollment in research. Pediatric Rheumatology, 2019, 17, 85.	0.9	5
64	Predicting Which Children with Juvenile Idiopathic Arthritis Will Not Attain Early Remission with Conventional Treatment: Results from the ReACCh-Out Cohort. Journal of Rheumatology, 2019, 46, 628-635.	1.0	24
65	Prospective Determination of the Incidence and Risk Factors of Newâ€Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Arthritis Care and Research, 2019, 71, 1436-1443.	1.5	26
66	European consensus-based recommendations for the diagnosis and treatment of rare paediatric vasculitides – the SHARE initiative. Rheumatology, 2019, 58, 656-671.	0.9	77
67	European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative. Rheumatology, 2019, 58, 672-682.	0.9	103
68	Understanding parent perceptions of healthy physical activity for their child with a chronic medical condition: A cross-sectional study. Paediatrics and Child Health, 2019, 24, e135-e141.	0.3	1
69	Strategies for Dealing with Missing Accelerometer Data. Rheumatic Disease Clinics of North America, 2018, 44, 317-326.	0.8	20
70	Similarity Network Fusion. Rheumatic Disease Clinics of North America, 2018, 44, 285-293.	0.8	5
71	American College of Rheumatology Provisional Criteria for Global Flares in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 813-822.	1.5	19
72	Alternative Design and Analytical Techniques for Longitudinal Rheumatology Studies. Rheumatic Disease Clinics of North America, 2018, 44, 189-201.	0.8	2

#	Article	IF	CITATIONS
73	Propensity Score Methods for Bias Reduction in Observational Studies of Treatment Effect. Rheumatic Disease Clinics of North America, 2018, 44, 203-213.	0.8	56
74	Applied Bayesian Methods in the Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2018, 44, 361-370.	0.8	4
75	Measuring Disease Damage and Its Severity in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 1621-1629.	1.5	28
76	The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology, 2018, 70, 669-678.	2.9	40
77	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	0.9	8
78	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). Clinical Trials, 2018, 15, 268-277.	0.7	19
79	Characteristics and Course of Enthesitis in a Juvenile Idiopathic Arthritis Inception Cohort. Arthritis Care and Research, 2018, 70, 303-308.	1.5	22
80	Healthâ€Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care and Research, 2018, 70, 134-144.	1.5	50
81	From Childhood to Adulthood: Disease Activity Trajectories in Childhoodâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2018, 70, 750-757.	1.5	18
82	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	2.0	29
83	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases, 2018, 77, 241-250.	0.5	36
84	Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 115-121.	1.0	10
85	CS-10â€Criteria for clinically relevant improvement in children & adolescents with childhood-onset systemic lupus erythematosus. , 2018, , .		0
86	A wearable activity tracker intervention for promoting physical activity in adolescents with juvenile idiopathic arthritis: a pilot study. Pediatric Rheumatology, 2018, 16, 66.	0.9	22
87	Assessment of limb edema in pediatric post-thrombotic syndrome. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 591-595.	1.0	0
88	Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematology,the, 2018, 5, e252-e260.	2.2	31
89	Characteristics of pain, other symptoms and function in pediatric postâ€thrombotic syndrome. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 334-338.	1.0	7
90	Preventing the Progression of Intestinal Failure–Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid. Journal of Parenteral and Enteral Nutrition, 2017, 41, 866-877.	1.3	111

#	Article	IF	CITATIONS
91	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenileâ€Onset Systemic Lupus Erythematosus. Arthritis Care and Research, 2017, 69, 1627-1635.	1.5	42
92	Consensus-based recommendations for the management of juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 329-340.	0.5	185
93	Comparative Effectiveness of Mycophenolate Mofetil for the Treatment of Juvenileâ€Onset Proliferative Lupus Nephritis. Arthritis Care and Research, 2017, 69, 1887-1894.	1.5	9
94	European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1637-1641.	0.5	75
95	Comparing the burden of illness of haemophilia between resourceâ€constrained and unconstrained countries: the São Paulo–Toronto Hemophilia Study. Haemophilia, 2017, 23, 682-688.	1.0	19
96	European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1788-1796.	0.5	139
97	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. Pediatric Rheumatology, 2017, 15, 18.	0.9	16
98	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 911-923.	2.9	59
99	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology. 2017, 69, 898-910.	2.9	52
100	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis. Annals of the Rheumatic Diseases, 2017, 76, 792-801.	0.5	92
101	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2017, 76, 782-791.	0.5	51
102	Magnetic resonance enterography has good inter-rater agreement and diagnostic accuracy for detecting inflammation in pediatric Crohn disease. Pediatric Radiology, 2017, 47, 565-575.	1.1	28
103	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Annals of the Rheumatic Diseases, 2017, 76, 1955-1964.	0.5	754
104	Validation of the Standardized Universal Pain Evaluations for Rheumatology Providers for Children and Youth (SUPER-KIDZ). Journal of Orthopaedic and Sports Physical Therapy, 2017, 47, 731-740.	1.7	13
105	European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Annals of the Rheumatic Diseases, 2017, 76, 1965-1973.	0.5	105
106	Exercise as Medicine for Children with Arthritis. Journal of Rheumatology, 2017, 44, 1103-1105.	1.0	2
107	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
108	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. Arthritis and Rheumatology, 2017, 69, 2271-2282.	2.9	391

#	Article	IF	CITATIONS
109	Clinical Trial Designs in Juvenile Idiopathic Arthritis. Current Treatment Options in Rheumatology, 2017, 3, 112-128.	0.6	0
110	Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash. Journal of Rheumatology, 2017, 44, 110-116.	1.0	43
111	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects. Rheumatology, 2017, 56, 1884-1893.	0.9	33
112	Cardiac findings in children with juvenile Dermatomyositis at disease presentation. Pediatric Rheumatology, 2017, 15, 54.	0.9	19
113	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	0.9	39
114	Costâ€Effectiveness Analysis of Firstâ€Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2016, 68, 1803-1811.	1.5	15
115	Knowledge translation in biostatistics: a survey of current practices, preferences, and barriers to the dissemination and uptake of new statistical methods. Statistics in Medicine, 2016, 35, 805-818.	0.8	13
116	Securing reimbursement for patient centered haemophilia care: major collaborative efforts are needed. Haematologica, 2016, 101, 266-268.	1.7	2
117	Enhancing translational research in paediatric rheumatology through standardization. Nature Reviews Rheumatology, 2016, 12, 684-690.	3.5	13
118	The Responsiveness of the Modified Childhood Health Assessment Questionnaire. Journal of Rheumatology, 2016, 43, 1904-1908.	1.0	5
119	Pilot study of onceâ€aâ€day prophylaxis for youth and young adults with severe haemophilia A. Haemophilia, 2016, 22, e401-5.	1.0	5
120	The Use of Neck Support Pillows and Postural Exercises in the Management of Chronic Neck Pain. Journal of Rheumatology, 2016, 43, 1871-1873.	1.0	5
121	Validation of Accelerometer Prediction Equations in Children with Chronic Disease. Pediatric Exercise Science, 2016, 28, 117-132.	0.5	20
122	Validity of the Stage of Exercise Scale in Children with Rheumatologic Conditions. Journal of Rheumatology, 2016, 43, 2189-2198.	1.0	8
123	Reply. Arthritis Care and Research, 2016, 68, 1049-1050.	1.5	1
124	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.5	72
125	Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory Myopathies. Journal of Rheumatology, 2016, 43, 169-176.	1.0	14
126	Ottawa Panel Evidence-Based Clinical Practice Guidelines for Foot Care in the Management of Juvenile Idiopathic Arthritis. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1163-1181.e14.	0.5	3

#	Article	IF	CITATIONS
127	Critical Appraisal of Studies Measuring Quality of Life in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2015, 67, 880-884.	1.5	5
128	A critical review of scoring options for clinical measurement tools. BMC Research Notes, 2015, 8, 612.	0.6	35
129	Abnormal Liver Biochemistry Is Common in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2848-2856.	0.9	20
130	Normal Values for Segmental Bioimpedance Spectroscopy in Pediatric Patients. PLoS ONE, 2015, 10, e0126268.	1.1	17
131	Assessing Activities, Participation, and Quality of Life in Hemophilia: Relevance, Current Limitations, and Possible Options. Seminars in Thrombosis and Hemostasis, 2015, 41, 894-900.	1.5	4
132	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 15970-15975.	3.3	139
133	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Annals of the Rheumatic Diseases, 2015, 74, 635-641.	0.5	145
134	Immunosuppressive Therapies for the Maintenance Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2015, 42, 1392-1400.	1.0	29
135	Recommendations for the management of autoinflammatory diseases. Annals of the Rheumatic Diseases, 2015, 74, 1636-1644.	0.5	239
136	Distinctions Between Diagnostic and Classification Criteria?. Arthritis Care and Research, 2015, 67, 891-897.	1.5	386
137	Expert Beliefs Regarding Novel Lipid-Based Approaches to Pediatric Intestinal Failure–Associated Liver Disease. Journal of Parenteral and Enteral Nutrition, 2014, 38, 702-710.	1.3	9
138	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. Arthritis and Rheumatology, 2014, 66, S220-S221.	2.9	7
139	Clinical Characteristics of Children With Juvenile Dermatomyositis: The Childhood Arthritis and Rheumatology Research Alliance Registry. Arthritis Care and Research, 2014, 66, 404-410.	1.5	82
140	Description of Active Joint Count Trajectories in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 2466-2473.	1.0	16
141	Trying to Improve Care: The Morbidity and Mortality Conference in a Division of Rheumatology. Journal of Rheumatology, 2014, 41, 2452-2458.	1.0	9
142	A26: Longitudinal Disease Trajectory of Juvenile Dermatomyositis. Arthritis and Rheumatology, 2014, 66, S41-S41.	2.9	2
143	A24: Validation of BASDAI and BASFI in Children with Spondyloarthritis. Arthritis and Rheumatology, 2014, 66, S38-S38.	2.9	7
144	The Relationship Between Physical Activity Levels and Pain in Children with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2014, 41, 345-351.	1.0	38

BRIAN M FELDMAN

#	Article	IF	CITATIONS
145	Parents' Willingness to Pay for Biologic Treatments in Juvenile Idiopathic Arthritis. Value in Health, 2014, 17, 830-837.	0.1	7
146	Chinese Hemophilia Joint Health Score 2.1 reliability study. Haemophilia, 2014, 20, 435-440.	1.0	43
147	Comparison of Average Weekly Pain Using Recalled Paper and Momentary Assessment Electronic Diary Reports in Children With Arthritis. Clinical Journal of Pain, 2014, 30, 1044-1050.	0.8	29
148	Hepatotoxicity Caused by Methotrexate Therapy in Children with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 47-59.	0.9	45
149	The Biologic Basis of Clinical Heterogeneity in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2014, 66, 3463-3475.	2.9	69
150	Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies. Journal of Clinical Epidemiology, 2014, 67, 401-409.	2.4	1,663
151	A15: Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis. Arthritis and Rheumatology, 2014, 66, S25-S25.	2.9	3
152	Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: A systematic review and network meta-analysis. Joint Bone Spine, 2014, 81, 337-341.	0.8	25
153	Systematic Review of the Quality of Prognosis Studies in Systemic Lupus Erythematosus. Arthritis Care and Research, 2014, 66, 1536-1541.	1.5	8
154	Maintien de la rémission sans biothérapie chez les patients adultes atteints de vascularite à ANCAÂ: revue systématique de la littérature et méta-analyse en réseau. Revue Du Rhumatisme (Edition) Tj ETQc	0 0.0 rgB]	[O verlock 1
155	Health outcomes of pediatric rheumatic diseases. Best Practice and Research in Clinical Rheumatology, 2014, 28, 331-350.	1.4	29
156	Predictors of Clinical Improvement in Rituximabâ€Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis. Arthritis and Rheumatology, 2014, 66, 740-749.	2.9	210
157	Using Value-of-Information Methods when the Disease Is Rare and the Treatment Is Expensive—The Example of Hemophilia A. Journal of General Internal Medicine, 2014, 29, 767-773.	1.3	12
158	Immunosuppressive Therapies for the Induction Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis. Journal of Rheumatology, 2014, 41, 1998-2007.	1.0	35
159	Determinants of quality of life in children with chronic somatic disease: pilot data from the GapS Questionnaire. Quality of Life Research, 2013, 22, 339-349.	1.5	2
160	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placeboâ€phase trial. Arthritis and Rheumatism, 2013, 65, 314-324.	6.7	514
161	Increased statistical power with combined independent randomization tests used with multiple-baseline design. Journal of Clinical Epidemiology, 2013, 66, 691-694.	2.4	5
162	Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. Journal of Thrombosis and Haemostasis, 2013, 11, 460-466.	1.9	43

#	Article	IF	CITATIONS
163	The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review. Seminars in Arthritis and Rheumatism, 2013, 42, 597-618.	1.6	42
164	An update on inflammatory myositis in children. Current Opinion in Rheumatology, 2013, 25, 630-635.	2.0	11
165	The Risky Business of Studying Prognosis. Journal of Rheumatology, 2013, 40, 9-15.	1.0	10
166	Doubly robust estimation, optimally truncated inverseâ€intensity weighting and incrementâ€based methods for the analysis of irregularly observed longitudinal data. Statistics in Medicine, 2013, 32, 1054-1072.	0.8	10
167	Drs. Lim and Feldman reply. Journal of Rheumatology, 2013, 40, 1771.2-1772.	1.0	Ο
168	Issues in the measurement of quality of life in hemophilia. Revista Brasileira De Hematologia E Hemoterapia, 2013, 35, 299-301.	0.7	4
169	BOLD MRI at 1.5 Tesla in juvenile idiopathic arthritis: preliminary experience. Clinics, 2013, 68, 721-724.	0.6	Ο
170	Later-onset rheumatoid factor negative polyarticular juvenile idiopathic arthritis (JIA): a unique patient group?. Clinical and Experimental Rheumatology, 2013, 31, 645-52.	0.4	4
171	Anti-signal Recognition Particle-positive Juvenile Polymyositis Successfully Treated with Rituximab. Journal of Rheumatology, 2012, 39, 1483.1-1485.	1.0	10
172	Warfarin in Systemic Sclerosis-associated and Idiopathic Pulmonary Arterial Hypertension. A Bayesian Approach to Evaluating Treatment for Uncommon Disease. Journal of Rheumatology, 2012, 39, 276-285.	1.0	75
173	Jointly managing arthritis. Journal of Child Health Care, 2012, 16, 124-140.	0.7	24
174	Neurodevelopment of Children Following Prenatal Exposure to Venlafaxine, Selective Serotonin Reuptake Inhibitors, or Untreated Maternal Depression. American Journal of Psychiatry, 2012, 169, 1165-1174.	4.0	157
175	Defining clinically inactive disease in juvenile dermatomyositis. Nature Reviews Rheumatology, 2012, 8, 638-639.	3.5	5
176	An update on the diagnosis and management of juvenile dermatomyositis. International Journal of Clinical Rheumatology, 2012, 7, 325-333.	0.3	2
177	Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment. Arthritis Care and Research, 2012, 64, 1382-1391.	1.5	26
178	Consensus treatments for moderate juvenile dermatomyositis: Beyond the first two months. Results of the Second Childhood Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2012, 64, 546-553.	1.5	101
179	The role of prothrombotic factors in the ocular manifestations of abusive and non-abusive head trauma: A feasibility study. Child Abuse and Neglect, 2012, 36, 333-341.	1.3	3
180	Haemophilia prophylaxis: how can we justify the costs?. Haemophilia, 2012, 18, 680-684.	1.0	17

#	Article	IF	CITATIONS
181	The Role of Parenteral Lipids in the Development of Advanced Intestinal Failure–Associated Liver Disease in Infants. Journal of Parenteral and Enteral Nutrition, 2011, 35, 596-602.	1.3	79
182	Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials. Journal of Clinical Epidemiology, 2011, 64, 286-292.	2.4	6
183	PubMed had a higher sensitivity than Ovid-MEDLINE in the search for systematic reviews. Journal of Clinical Epidemiology, 2011, 64, 805-807.	2.4	20
184	Juvenile Dermatomyositis. Current Rheumatology Reports, 2011, 13, 216-224.	2.1	39
185	Costâ€effectiveness of biologics in polyarticularâ€course juvenile idiopathic arthritis patients unresponsive to diseaseâ€modifying antirheumatic drugs. Arthritis Care and Research, 2011, 63, 111-119.	1.5	32
186	Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care and Research, 2011, 63, 223-230.	1.5	224
187	Effect of Warfarin on Survival in Scleroderma-associated Pulmonary Arterial Hypertension (SSc-PAH) and Idiopathic PAH. Belief Elicitation for Bayesian Priors. Journal of Rheumatology, 2011, 38, 462-469.	1.0	30
188	Using an electronic pain diary to better understand pain in children and adolescents with arthritis. Pain Management, 2011, 1, 127-137.	0.7	10
189	Improving the assessment of children with JIA. Nature Reviews Rheumatology, 2011, 7, 442-444.	3.5	6
190	Efficacy of intravenous Ig therapy in juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2011, 70, 2089-2094.	0.5	70
191	Predictors of Hip Disease in the Systemic Arthritis Subtype of Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2011, 38, 954-958.	1.0	14
192	Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology, 2011, 50, 885-893.	0.9	61
193	Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care and Research, 2010, 62, 465-472.	1.5	204
194	Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care and Research, 2010, 62, 527-536.	1.5	86
195	Protocols for the initial treatment of moderately severe juvenile dermatomyositis: Results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care and Research, 2010, 62, 219-225.	1.5	77
196	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care and Research, 2010, 62, 1533-1541.	1.5	84
197	Rheumatic Disease and Carotid Intima-Media Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1014-1026.	1.1	166
198	An Internet-based Self-management Program with Telephone Support for Adolescents with Arthritis: A Pilot Randomized Controlled Trial. Journal of Rheumatology, 2010, 37, 1944-1952.	1.0	184

#	Article	IF	CITATIONS
199	Treatment of Pediatric Localized Scleroderma: Results of a Survey of North American Pediatric Rheumatologists. Journal of Rheumatology, 2010, 37, 175-181.	1.0	76
200	Methods to elicit beliefs for Bayesian priors: a systematic review. Journal of Clinical Epidemiology, 2010, 63, 355-369.	2.4	140
201	A valid and reliable belief elicitation method for Bayesian priors. Journal of Clinical Epidemiology, 2010, 63, 370-383.	2.4	66
202	Response times follow lognormal or gamma distribution in arthritis patients. Journal of Clinical Epidemiology, 2010, 63, 1363-1369.	2.4	6
203	Treatment Approaches to Juvenile Dermatomyositis (JDM) Across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. Journal of Rheumatology, 2010, 37, 1953-1961.	1.0	90
204	Usability Testing of an Online Self-management Program for Adolescents With Juvenile Idiopathic Arthritis. Journal of Medical Internet Research, 2010, 12, e30.	2.1	125
205	Comparison of Patients with Juvenile Psoriatic Arthritis and Nonpsoriatic Juvenile Idiopathic Arthritis: How Different Are They?. Journal of Rheumatology, 2009, 36, 2033-2041.	1.0	36
206	A Qualitative Study of Fitness Instructors' Experiences Leading an Exercise Program for Children with Juvenile Idiopathic Arthritis. Physical and Occupational Therapy in Pediatrics, 2009, 29, 409-425.	0.8	9
207	Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis and Rheumatism, 2009, 60, 3425-3435.	6.7	107
208	Designing an oral mucositis assessment instrument for use in children: generating items using a nominal group technique. Supportive Care in Cancer, 2009, 17, 555-562.	1.0	22
209	Predicting time to remission of juvenile dermatomyositis: the role of clinical features. International Journal of Clinical Rheumatology, 2009, 4, 387-389.	0.3	0
210	Shifting Our Thinking About Uncommon Disease Trials: The Case of Methotrexate in Scleroderma. Journal of Rheumatology, 2009, 36, 323-329.	1.0	71
211	Understandability, Content Validity, and Overall Acceptability of the Children's International Mucositis Evaluation Scale (ChIMES). Journal of Pediatric Hematology/Oncology, 2009, 31, 416-423.	0.3	20
212	Quality, not just quantity: the role of qualitative methods in anesthesia research. Canadian Journal of Anaesthesia, 2008, 55, 670-673.	0.7	6
213	Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. Pediatric Rheumatology, 2008, 6, 5.	0.9	24
214	Asking the experts: Exploring the selfâ€management needs of adolescents with arthritis. Arthritis and Rheumatism, 2008, 59, 65-72.	6.7	122
215	The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis. Arthritis and Rheumatism, 2008, 59, 989-995.	6.7	52
216	Predicting the course of juvenile dermatomyositis: Significance of early clinical and laboratory features. Arthritis and Rheumatism, 2008, 58, 3585-3592.	6.7	95

#	Article	IF	CITATIONS
217	Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting. Journal of Clinical Epidemiology, 2008, 61, 875-881.	2.4	11
218	Construct validity of a multidimensional electronic pain diary for adolescents with arthritis. Pain, 2008, 136, 281-292.	2.0	109
219	Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet, The, 2008, 371, 2201-2212.	6.3	383
220	Safety of Intravenous Immunoglobulin in the Treatment of Juvenile Dermatomyositis: Adverse Reactions Are Associated With Immunoglobulin A Content. Pediatrics, 2008, 121, e626-e630.	1.0	49
221	Economics of preventing premature mortality and impaired cognitive development in children through home-fortification: A health policy perspective. International Journal of Technology Assessment in Health Care, 2008, 24, 303-311.	0.2	8
222	Working Out the Kinks: Testing the Feasibility of an Electronic Pain Diary for Adolescents with Arthritis. Pain Research and Management, 2008, 13, 375-382.	0.7	39
223	Childhood stroke as the presentation of Takayasu's arteritis: diagnostic delay can cause catastrophic complications. Journal of Rheumatology, 2008, 35, 1228-30.	1.0	6
224	Sinus Bradycardia After Intravenous Pulse Methylprednisolone. Pediatrics, 2007, 119, e778-e782.	1.0	63
225	Inflammatory Myopathies in Children. Rheumatic Disease Clinics of North America, 2007, 33, 525-553.	0.8	12
226	Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 631-638.	6.7	36
227	The effects of vigorous exercise training on physical function in children with arthritis: A randomized, controlled, SINGLEâ€BLINDED trial. Arthritis and Rheumatism, 2007, 57, 1202-1210.	6.7	92
228	Classification criteria in rheumatic diseases: A review of methodologic properties. Arthritis and Rheumatism, 2007, 57, 1119-1133.	6.7	122
229	Reliability of exercise testing and functional activity questionnaires in children with juvenile arthritis. Arthritis and Rheumatism, 2007, 57, 1446-1452.	6.7	33
230	Validation of the oral mucositis assessment scale in pediatric cancer. Pediatric Blood and Cancer, 2007, 49, 149-153.	0.8	35
231	10 Year Musculoskeletal Outcomes with Tailored Primary Prophylaxis: The Canadian Hemophilia Prophylaxis Study Blood, 2007, 110, 84-84.	0.6	3
232	The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patients. Journal of Rheumatology, 2007, 34, 581-7.	1.0	21
233	Amitriptyline to relieve pain in juvenile idiopathic arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 clinical trials. Journal of Rheumatology, 2007, 34, 1125-32.	1.0	30
234	Classification criteria for systemic sclerosis subsets. Journal of Rheumatology, 2007, 34, 1855-63.	1.0	34

#	Article	IF	CITATIONS
235	Childhood acquired lipodystrophy: AÂretrospectiveÂstudy. Journal of the American Academy of Dermatology, 2006, 55, 947-950.	0.6	62
236	Physiologic mechanisms can predict hematologic responses to iron supplements in growing children: a computer simulation model. American Journal of Clinical Nutrition, 2006, 83, 681-687.	2.2	4
237	e-Ouch: Usability Testing of an Electronic Chronic Pain Diary for Adolescents With Arthritis. Clinical Journal of Pain, 2006, 22, 295-305.	0.8	111
238	Advances in the treatment of juvenile dermatomyositis. Current Opinion in Rheumatology, 2006, 18, 503-506.	2.0	37
239	N-of-1 Trials: Innovative Methods to Evaluate Complementary and Alternative Medicines in Pediatric Cancer. Journal of Pediatric Hematology/Oncology, 2006, 28, 263-266.	0.3	21
240	Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. Journal of Thrombosis and Haemostasis, 2006, 4, 1228-1236.	1.9	224
241	A critical appraisal of radiographic scoring systems for assessment of juvenile idiopathic arthritis. Pediatric Radiology, 2006, 36, 759-772.	1.1	38
242	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. Arthritis and Rheumatism, 2006, 54, 1283-1290.	6.7	25
243	Corticosteroid treatment of refractory Kawasaki disease. Journal of Rheumatology, 2006, 33, 803-9.	1.0	25
244	The Relationship Between Function, Self-perception, and Spinal Deformity. Journal of Pediatric Orthopaedics, 2005, 25, 64-69.	0.6	35
245	International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2005, 52, 2607-2615.	6.7	146
246	The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis and Rheumatism, 2005, 52, 3570-3578.	6.7	149
247	Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. Arthritis and Rheumatism, 2005, 53, 897-904.	6.7	22
248	Long-term outcomes in juvenile dermatomyositis: How did we get here and where are we going?. Current Rheumatology Reports, 2005, 7, 441-446.	2.1	48
249	Inflammatory Myopathies in Children. Pediatric Clinics of North America, 2005, 52, 493-520.	0.9	37
250	Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. Journal of Clinical Epidemiology, 2005, 58, 261-268.	2.4	125
251	Treating children with arthritis: towards an evidence-based culture. Journal of rheumatology Supplement, The, 2005, 72, 33-5.	2.2	4
252	Eye findings in patients with juvenile dermatomyositis. Journal of Rheumatology, 2005, 32, 1986-91.	1.0	22

#	Article	IF	CITATIONS
253	Inpatient Versus Outpatient Management of Low-Risk Pediatric Febrile Neutropenia: Measuring Parents' and Healthcare Professionals' Preferences. Journal of Clinical Oncology, 2004, 22, 3922-3929.	0.8	66
254	Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis and Rheumatism, 2004, 50, 1595-1603.	6.7	195
255	Revised versions of the Childhood Health Assessment Questionnaire (CHAQ) are more sensitive and suffer less from a ceiling effect. Arthritis and Rheumatism, 2004, 51, 881-889.	6.7	56
256	Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. Journal of Pediatrics, 2004, 144, 490-495.	0.9	49
257	Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. Journal of Pediatrics, 2004, 145, 628-634.	0.9	39
258	Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritis. Journal of Rheumatology, 2004, 31, 2068-70.	1.0	17
259	The randomized placebo-phase design for clinical trials. Physical Therapy in Sport, 2003, 4, 129-136.	0.8	2
260	European Consensus Lupus Activity Measurement is sensitive to change in disease activity in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 49, 335-341.	6.7	52
261	Vitamin E: The Evidence for Multiple Roles in Cancer. Nutrition and Cancer, 2003, 46, 1-14.	0.9	31
262	Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. British Journal of Rheumatology, 2003, 42, 1452-1459.	2.5	209
263	Pagers in a busy paediatric emergency waiting room: A randomized controlled trial. Paediatrics and Child Health, 2003, 8, 422-426.	0.3	4
264	Item weightings for the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index using Rasch analysis do not lead to an important improvement. Journal of Rheumatology, 2003, 30, 292-7.	1.0	17
265	Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheumatic Disease Clinics of North America, 2002, 28, 833-857.	0.8	145
266	Health-related quality of life in children with arthritis. Rheumatic Disease Clinics of North America, 2002, 28, 493-501.	0.8	17
267	Risk factors for damage in childhood-onset systemic lupus erythematosus: Cumulative disease activity and medication use predict disease damage. Arthritis and Rheumatism, 2002, 46, 436-444.	6.7	278
268	Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. Journal of Rheumatology, 2002, 29, 490-501.	1.0	27
269	Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 1071-8.	1.0	20
270	The randomized placebo-phase design for clinical trials. Journal of Clinical Epidemiology, 2001, 54, 550-557.	2.4	42

#	Article	IF	CITATIONS
271	A three-stage clinical trial design for rare disorders. Statistics in Medicine, 2001, 20, 3009-3021.	0.8	30
272	The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis and Rheumatism, 2001, 44, 1768-1774.	6.7	137
273	Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis and Rheumatism, 2000, 43, 541.	6.7	234
274	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis and Rheumatism, 2000, 43, 2402-2409.	6.7	124
275	Children with morphea have normal self-perception. Journal of Pediatrics, 2000, 137, 727-730.	0.9	23
276	Methotrexate and corticosteroid therapy for pediatric localized scleroderma. Journal of Pediatrics, 2000, 136, 91-95.	0.9	208
277	Sensitivity of the systemic lupus erythematosus disease activity index, British Isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis and Rheumatism, 1999, 42, 1354-1360.	6.7	180
278	Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. Journal of Pediatrics, 1998, 132, 109-116.	0.9	69
279	General and local scleroderma in children and dermatomyositis and associated syndromes. Current Opinion in Rheumatology, 1997, 9, 458-464.	2.0	8
280	Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. I. Physician, parent, and patient global assessments. Arthritis and Rheumatism, 1997, 40, 1976-1983.	6.7	127
281	Seasonal onset of systemic-onset juvenile rheumatoid arthritis. Journal of Pediatrics, 1996, 129, 513-518.	0.9	45
282	Serum levels of soluble interleukin-2 receptor. Arthritis and Rheumatism, 1994, 37, 898-901.	6.7	58
283	Diagnostic use of B-cell alloantigen D8/17 in rheumatic chorea. Journal of Pediatrics, 1993, 123, 84-86.	0.9	35
284	Validation of the parent global assessment as a health-related quality of life measure in juvenile idiopathic arthritis: Results from ReACCh-Out. Rheumatology, 0, , .	0.9	2